• All
  • 2cureX
  • Agillic
  • Amniotics
  • Aquaporin
  • Argeo
  • Ascelia Pharma
  • Asetek
  • Astralis
  • Audientes
  • BankNordik
  • Bawat
  • Better Collective
  • BioPorto
  • BoMill
  • Boozt
  • Curasight
  • DanCann Pharma
  • Danish Aerospace company
  • Danske Bank
  • DecideAct
  • DFDS
  • Digizuite
  • Djurslands Bank
  • Evaxion-Biotech
  • ExpreS2ion Biotechnologies
  • FirstFarms
  • Flügger
  • Gabriel
  • Green Hydrogen Systems
  • GreenMobility
  • H+H International
  • Hafnia
  • Hansa BioPharma
  • HusCompagniet
  • Hydract
  • Idogen
  • Impero
  • InDex Pharmaceuticals
  • MapsPeople
  • Movinn
  • NeoDynamics
  • Nexcom
  • Nordic Solar
  • North Media
  • NTG - Nordic Transportation Group
  • Odico
  • OmniCar
  • OrderYOYO
  • Penneo
  • Photocat
  • Re-Match
  • River Tech
  • Roblon
  • Sanistaal
  • Scandinavian Medical Solutions
  • Scape Technologies
  • Skako
  • Skjern Bank
  • SP Group
  • Sparekassen Sjælland-Fyn
  • Tryg
  • Valuer
  • Virogates
  • Windowmaster
  • Xplora Technologies
Sparekassen Sjælland-Fyn

Sparekassen Sjælland-Fyn: Investorpræsentation, oktober 2022

Vi har i HC Andersen Capital, som annonceret tidligere på måneden, indledt samarbejde med Sparekassen Sjælland-Fyn. Vi er glade og stolte over at kunne tilføje …

Read More →

NeoDynamics has received FDA approval for the NeoNavia pulse biopsy system

The medTech company NeoDynamics has received approval for its innovative pulse biopsy system NeoNavia® from the US Food and Drug Administration, FDA. The US breast …

Read More →

BioStock interviews Christina Herder new CEO in Idogen

Idogen is a company developing tolerogenic cell therapies to treat conditions or diseases caused by an unwanted immune response in the patient. The candidate drug …

Read More →

Flad omsætning, men et vist indtjeningspres i Q1 2022/23

Flügger group A/S har her midt på dagen udsendt regnskab for 1. kvartal 2022/23, hvor de nyligt opdaterede helårsforventninger til 2022/23 fastholdes. Selve kvartalet viser en …

Read More →

Redeye updates their analysis of Idogen AB as the company approaches clinical phase

Idogen is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in …

Read More →

PhD Marcus Larsson – new CEO for Amniotics

Amniotics announced this week that the board of directors has resolved to appoint PhD Marcus Larsson as new Chief Executive Officer (CEO) of Amniotics. Marcus …

Read More →

Erik Penser Bank initiates coverage of Idogen

Idogen develops tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response. In conjunction when the company is …

Read More →

Amniotics – Report for the Second Quarter 2022

April – June in brief Other events after the end of the reporting period The company received approval by regulatory authorities in UK and Sweden …

Read More →

Amniotics AB Phase I/II study of PulmoStem in hospitalized COVID-19 patients is ready to start!

Amniotics today announced that several batches of PulmoStem have been certified by the company’s Qualified Person (QP) and that clinical sites in the UK and …

Read More →